An observational study in Heart Valve Diseases, Health Behavior and Postoperative Period, sponsored by Fujian Medical University Union Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-07-08.
Sponsored by Fujian Medical University Union Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Heart Valve Diseases with a site in China — 28 open to participants now, 30 under way, none of them phase 3. Heart Valve Diseases · China.
Among the 69 studies in Heart Valve Diseases with a site in China, this one is the 31st largest by planned enrollment of the 35 observational ones that give a count, is one of 9 that started in 2024, is one of 35 observational ones, reaches primary completion later than 4 of the 29 other live ones, and was the 56th registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →28 of the 69 studies in Heart Valve Diseases with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+ · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1 · Phase 4 3
First in 2000; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 219 is below the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Median enrollment 200 across the 34 interventional studies, 3,000 across the 35 observational. Of the 18 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 69 have an industry lead sponsor. The 10 most frequent:
Fujian Medical University Union Hospital is the lead sponsor of 109 studies on the registry; 79 are open to participants now.
Fujian Medical University Union Hospital has 1 study filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Valve Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05397392Nanjing First Hospital, Nanjing Medical UniversityResearch on Optimal Diagnosis and Treatment of Cardiorenal Syndrome | 2026-12 |
| NCT07816146Yongjian Wu, MD, PhDChina Elderly Valve Disease Study III (China-DVD3 Study) | 2026-12-31 |
| NCT03011697Second Affiliated Hospital, School of Medicine, Zhejiang UniversityValvular Heart Disease Registry Study in Second Affiliated Hospital of ZheJiang University | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 69 studies in Heart Valve Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigates the influencing factors and the pathways of health behavior in patients after heart valve replacement.
Currently, the prevalence of heart valve disease is 2.0% to 13.2%, and heart valve replacement is the most important treatment to address heart valve disease. Heart valve replacement surgery is highly traumatic and risky, and the recovery of physiological, psychological, and social functions of postoperative patients is challenging, affecting the recovery process of patients. Healthy behavior is a lifestyle that can effectively reduce risk factors for adverse events and complications at the physiological, psychological, and social levels to slow disease progression, which can help promote patient recovery and improve prognosis. Therefore, this study investigates and analyzes the health behaviors of postoperative patients in different periods, explores their influencing factors and analyzes their pathways of action.
Patients undergoing postoperative heart valve replacement were selected for the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Health behavior
A set of behavioral activities undertaken by an individual to promote or maintain health.
Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.
Social support
Support received by an individual from within a social relationship.
Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.
Anxiety and depression
Measuring the psychological situation.
Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.
Self-efficacy
Measure the level of self-confidence.
Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.
Medication Literacy
Measuring medication-taking skills.
Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Nov 2024, 10 months after the start.
Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 10 months is below that.
Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fujian Medical University Union Hospital →